India’s drug regulatory force conducts third round of raids on manufacturers

Indian flag
The regulatory agency found both firms were producing new drug formulations without regulatory approval. (Yann Forget/Wikimedia Commons)

India’s drug regulatory force, the Central Drugs Standards Control Organization, pulled off a third round of raids on drug facilities that were manufacturing products without approval.

In the latest round of raids, the agency focused on manufacturing firms in Sikkim that resulted in the cancellation of one license and suspension of another, The Wire reported.

The raids last week, which come in the wake of similar actions in Uttarakhand and Daman, targeted drug manufacturing firms Savi Healthsciences and Savi Pharma.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The regulatory agency found both firms were producing new drug formulations of ulipristal, dienogest and azilsartan without regulatory approval. Ulipristal is an emergency contraceptive, dienogest is a hormonal drug used to treat endometriosis in women, and azilsartan is used to treat high blood pressure.

The agency cancelled Savi Pharma’s license and ordered it to dispose of all processed tablets, capsules and sterile products.

In the case of the raid on Savi Healthsciences, inspectors found the firm was manufacturing drugs in areas of the plant that were under construction. The company was also cited for not keeping appropriate records of their manufacturing process.

Read more on

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.